PTO/SB/26 (08-03)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

## TERMINAL DISCLAIMER TO OBVIATE A DOUBLE PATENTING REJECTION OVER A PRIOR PATENT

Docket Number (Optional)

REJECTION OVER A PRIOR PATENT 98-164-A24

In re Application of: Wolff		
Application No.: 10/614,460		
Filed: July 7, 2003		
For: Sustained Release Ranolazine Formulations		
The owner*, C.V. Therapeutics, Inc., of 100 disclaims, except as provided below, the terminal part of the state which would extend beyond the expiration date of the full state shortened by any terminal disclaimer, of prior Patent No. 6,620 so granted on the instant application shall be enforceable only commonly owned. This agreement runs with any patent granted its successors or assigns.	tory term defined in 35 U.S.C. 154 ,814	the instant application, and 173, as presently agrees that any patent and the prior patent are
In making the above disclaimer, the owner does not discapplication that would extend to the expiration date of the full sprior patent, as presently shortened by any terminal disclaim maintenance fee, is held unenforceable, is found invalid by a whole or terminally disclaimed under 37 CFR 1.321, has all clais in any manner terminated prior to the expiration of its fur disclaimer.	statutory term as defined in 35 U.S. er, in the event that it later: expire court of competent jurisdiction, is s ms canceled by a reexamination cere.	C. 154 and 173 of the es for failure to pay a tatutorily disclaimed in rtificate, is reissued, or
Check either box 1 or 2 below, if appropriate.		
1. XX For submissions on behalf of an organization (e.g., corport etc.), the undersigned is empowered to act on behalf of		ernment agency,
I hereby declare that all statements made herein of my information and belief are believed to be true; and further that th false statements and the like so made are punishable by fine or the United States Code and that such willful false statements m issued thereon.	ese statements were made with the imprisonment, or both, under Section	knowledge that willful on 1001 of Title 18 of
2 The condensioned is an observed as a condension of second		
2 The undersigned is an attorney or agent of record.	Lanar	6/22/04
	Signature	Date
	•	
	Louis G. Lange	
•	Typed or printed name	
	(650) 384-8501	
	Telephone Number	•
Terminal disclaimer fee under 37 CFR 1.20(d) included.		•
WARNING: Information on this form may become p		
be included on this form. Provide credit card inforn	nation and authorization on PTO-2038.	·
*Statement under 37 CFR 3.73(b) is required if terminal disclaim Form PTO/SB/96 may be used for making this certification. See	· · · · · · · · · · · · · · · · · · ·	, in the second

This collection of information is required by 37 CFR 1.321. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

07/01/2004 CCHAU1 00000156 501789 10614460